Search results for "Aggregation"

showing 10 items of 566 documents

The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.

2019

International audience; Background: The COMPASS trial assessed the impact of adding low dose rivaroxaban to aspirin in selected patients (pts). After an acute myocardial infarction (MI), when dual antiplatelet treatment is no longer needed, patients might be eligible for aspirin/rivaroxaban co-therapy. The characteristics and risks of such a population are unclear.Methods: Data were extracted from the FAST-MI 2005, 2010 and 2015 nationwide French registries. Characteristics and long-term mortality were compared according to COMPASS eligibility and between registry and trial populations.Results: Among 9954 patients alive and free of events at one year, 4402 (44%) were classified as COMPASS-L…

Malemedicine.medical_specialtyanimal structuresPopulationMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery diseaseCohort Studies03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRandomized controlled trialRivaroxabanlawCompassInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionRegistrieseducationAgedAged 80 and overIschemic and hemorrhagic riskAspirinRivaroxabaneducation.field_of_studyAspirinbusiness.industryAnticoagulantsMiddle Agedmedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthIncreased risk[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyPopulation SurveillanceCOMPASS study[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyFemaleFranceCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFollow-Up StudiesInternational journal of cardiology
researchProduct

The Prescription of Vitamin K Antagonists in a Very Old Population: A Cross-Sectional Study of 8696 Ambulatory Subjects Aged Over 85 Years

2020

We compared very elderly people taking vitamin K antagonists (VKA) and those not taking VKA (noVKA). Individuals were included in the noVKA group if there was no VKA on their reimbursed prescriptions during the study period. We also compared three subgroups, constituted by VKA type (fluindione, warfarin, or acenocoumarol). We included individuals aged over 85 years, affiliated to Mutualit&eacute

Malemedicine.medical_specialtyanticoagulantsVitamin KCross-sectional studyHealth Toxicology and MutagenesisPopulationlcsh:Medicine030204 cardiovascular system & hematologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicinePractice Patterns Physicians'Medical prescriptioneducationAgedAged 80 and overeducation.field_of_studyAcenocoumaroldrug prescriptionFluindionebusiness.industrylcsh:RPublic Health Environmental and Occupational HealthWarfarinaged 80 and overoutpatientsCross-Sectional StudiesPrescriptionschemistryAmbulatoryPlatelet aggregation inhibitorFemaleWarfarinbusinessmedicine.drugInternational Journal of Environmental Research and Public Health
researchProduct

Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

2020

Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the r…

Malemedicine.medical_specialtyaspirinHealth Toxicology and Mutagenesisdipyridamolelcsh:MedicineStroke.Review030204 cardiovascular system & hematology03 medical and health sciencesTherapeutic approach0302 clinical medicinePharmacotherapyDouble-Blind MethodpreventionSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineStrokeAgedclopidogrelAspirinPreventive strategybusiness.industrylcsh:RPublic Health Environmental and Occupational HealthMiddle AgedClopidogrelmedicine.diseasestrokecombined drug therapyClinical trialDiabetes Mellitus Type 2Ischemic Attack TransientStroke preventionDrug Therapy CombinationFemalebusinesscilostazolPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drugInternational Journal of Environmental Research and Public Health
researchProduct

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Anticoagulation prescription in atrial fibrillation.

2011

We seek to assess the factors associated with the anticoagulation prescription in a cohort of patients with atrial fibrillation (AF) collected from out-patient clinics.A total of 1524 patients with a history of AF were collected from out-patients clinics. CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores were calculated in every patient. Variables associated with anticoagulant treatment prescription were analyzed in univariant and multivariant models.Most patients received either anticoagulant (62%) or antiplatelet treatment (37%). Anticoagulation rates increased among higher CHADS(2) and CHA(2)DS(2)-VASc score values. A logistic regression model was performed to assess the variables associate…

Malemedicine.medical_specialtymedicine.drug_classHemorrhageLogistic regressionAmbulatory Care FacilitiesRisk FactorsInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Medical prescriptionPractice Patterns Physicians'AgedPharmacologyAged 80 and overbusiness.industryAnticoagulantAnticoagulantsAtrial fibrillationThrombosisGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLogistic ModelsAnticoagulant therapyConcomitantCohortMultivariate AnalysisCardiologyFemalebusinessPlatelet Aggregation InhibitorsExpert opinion on pharmacotherapy
researchProduct

Effects of endotoxin on neurally-mediated gastric acid secretion in the rat.

1998

Abstract The effects of a peripheral administration of E. coli endotoxin on neurally-mediated gastric acid secretion and the role of endogenous opioids or PAF receptors in endotoxin effects have been evaluated in the continuously perfused stomach of the anaesthetized rat. Gastric acid secretion stimulated by distension (20 cm H2O) was reduced dose-dependently by single intravenous bolus injection of endotoxin (0.1–10 μg kg−1). Doses of 5 μg kg−1 induced a peak reduction of distension-stimulated acid output and significantly reduced the secretory response induced by an intravenous bolus of 2-deoxy-d-glucose (150 mg kg−1). This dose of endotoxin did not significantly modify mean systemic arte…

Malemedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceBlood PressureReceptors Cell Surface(+)-NaloxonePlatelet Membrane GlycoproteinsDistensionDeoxyglucoseReceptors G-Protein-CoupledGastric AcidOpioid receptorInternal medicinemedicineEscherichia coliAnimalsRats WistarEndogenous opioidPharmacologyDose-Response Relationship Drugbusiness.industryNaloxoneGastric distensionStomachAntagonistAzepinesTriazolesReceptor antagonistRatsEndotoxinsEndocrinologyOpioid PeptidesReceptors OpioidGastric acidFemalemedicine.symptombusinessPlatelet Aggregation InhibitorsThe Journal of pharmacy and pharmacology
researchProduct

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer

2016

Abstract Background The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n = 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients no…

Malemedicine.medical_specialtymedicine.drug_classUrology030232 urology & nephrologyLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansAntiplateletStage (cooking)Macroscopic hematuriaAnticoagulant; Antiplatelet; Bladder cancer; Emergency room; Hematuria; Non-muscle invasive bladder cancerEarly Detection of CancerRetrospective StudiesHematuriaAgedNeoplasm StagingBladder cancerbusiness.industryPlatelet Aggregation InhibitorAnticoagulantBladder cancerAnticoagulantAnticoagulantsRetrospective cohort studyEmergency roomOdds ratioMiddle Agedmedicine.diseaseSurgeryUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmPlatelet aggregation inhibitorFemalebusinessNon-muscle invasive bladder cancerPlatelet Aggregation InhibitorsHuman
researchProduct

Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral …

2017

Abstract Background Patients with peripheral artery disease (PAD) undergoing a lower-extremity revascularization are at heightened risk for ischemic cardiac and limb events. Although intensification of antithrombotic therapy after revascularization has demonstrated benefit in coronary disease populations, this approach has not been well studied or shown consistent benefit in PAD. Recent trial evidence demonstrated that a treatment strategy of rivaroxaban added to background antiplatelet therapy reduced ischemic risk in patients following recent acute coronary syndromes, as well as in patients with stable atherosclerotic vascular disease. Whether these benefits extend to the population of pa…

Malemedicine.medical_specialtymedicine.medical_treatmentPopulation030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialDouble-Blind MethodRivaroxabanlawInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctioneducationRivaroxabaneducation.field_of_studyAspirinDose-Response Relationship Drugbusiness.industryEndovascular ProceduresThrombolysisMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeLower ExtremityCardiologyPurinergic P2Y Receptor AntagonistsPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsFollow-Up StudiesAmerican heart journal
researchProduct

Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke.

2014

Background Hemorrhagic transformation (HT), a complication of ischemic stroke (IS), might influence patient's prognosis. Our aim is to evaluate, in a hospital-based series of patients not treated with thrombolysis, the relationship between HT and mortality. Methods We compared mortality of individuals with spontaneous HT with that of individuals without. Medical records of patients diagnosed with anterior IS were retrospectively reviewed. Outcome measures were 30- and 90-day survival after IS onset. Kaplan–Meier estimates were used to construct survival curves. Cox proportional hazards model was used to estimate hazard ratio (HR) for the main outcome measure (death). HT was stratified in he…

Malemedicine.medical_specialtysurvivalBrain IschemiaCohort StudiesHematomaRisk FactorsInternal medicineMedicineHumansStrokeSurvival analysisAgedRetrospective StudiesAged 80 and overIschemic strokeAspirinbusiness.industryProportional hazards modelHeparinMortality rateRehabilitationHazard ratioAnticoagulantsIschemic stroke; epidemiology; hemorrhagic transformation; prognosis; survivalMiddle Agedmedicine.diseaseConfidence intervalSurgeryStrokeSurvival Ratehemorrhagic transformationCardiologyDisease ProgressionepidemiologySettore MED/26 - NeurologiaSurgeryFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessComplicationIntracranial HemorrhagesprognosiPlatelet Aggregation InhibitorsFollow-Up StudiesJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
researchProduct

Aggregation methods to calculate the average price

2015

Abstract Average price is a numerical value that represents a set of prices, which may relate to firms, countries, or regions. This study presents new methods of average price aggregation that build on the unified aggregation operator (UAO). The UAO combines a wide range of sub-aggregation processes into a single formulation capable of accounting for the importance of each concept in the analysis. The aggregation system is flexible, can adapt to different environments, and provides a complete representation of relevant information. The UAO can calculate the average price for numerous geographical contexts such as supranational regions and countries. The study illustrates the UAO's utility b…

MarketingSet (abstract data type)Operator (computer programming)Average priceValue (economics)EconometricsRange (statistics)EconomicsProduct (category theory)Representation (mathematics)Aggregation methodsJournal of Business Research
researchProduct